EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy in bone and soft-tissue tumors: Current advances and future directions

Li Fang, Chong Zheng, Haijun Tang, Jian Li, Haohong Zheng, Bin Yang, Xiaodan Li, Jian Wang, Jianlong Li

Orthopedics and Tissue Engineering · 20.02.2026 · 1 (2) · 025360015

DOI: 10.36922/ote025360015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Orthopedics and Tissue Engineering, online erschienen am 20.02.2026. Verfasst von Li Fang und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has emerged as a transformative strategy for treating bone and soft-tissue sarcomas, a class of rare, heterogeneous malignancies originating from mesenchymal tissues; however, significant challenges remain. This narrative review summarizes recent advances in sarcoma immunotherapy, covering molecular mechanisms, tumor microenvironment (TME) characteristics, and treatment responses specific to major subtypes such as osteosarcoma, liposarcoma, and synovial sarcoma. Notably, despite being a distinct myeloid neoplasm rather than a sarcoma, systemic mastocytosis is included in this study to identify common therapeutic targets through cross-disease comparisons (e.g., kinase-driven pathways and mechanisms regulating the immunosuppressive TME). Clinical data indicate that single-agent immune checkpoint inhibitors (ICIs) produce limited objective response rates in advanced sarcomas (approximately 16.7%), with significant efficacy disparities across subtypes, ranging from high response rates in alveolar soft part sarcomas to minimal responses in osteosarcomas. Key resistance mechanisms include a suppressive TME dominated by myeloid-derived suppressor cells, low tumor mutational burden, and antigenic heterogeneity. Combination strategies such as ICIs with radiotherapy, tyrosine kinase inhibitors, or anti-angiogenic agents significantly improve outcomes. Emerging cell therapies such as chimeric antigen receptor T-cell, T-cell receptor–engineered, and tumor-infiltrating lymphocyte therapies, combined with neoantigen vaccines and nanotechnology-driven delivery systems, demonstrate potential in reshaping the TME and overcoming immune escape. Biomarkers, including programmed death-ligand 1 expression, tertiary lymphoid structures, and immune gene profiles, hold prognostic value but require further validation. Future research should prioritize tissue-specific trial designs, combined TME remodeling regimens, and biomarker-guided personalized therapies to effectively convert “cold” sarcomas into immunotherapy-responsive malignancies.

Zitieren

APA

Fang, L., Zheng, C., Tang, H., Li, J., Zheng, H., Yang, B., Li, X., Wang, J., & Li, J. (2026). Immunotherapy in bone and soft-tissue tumors: Current advances and future directions. Orthopedics and Tissue Engineering, 1(2), 025360015. https://doi.org/10.36922/ote025360015

Vancouver

Fang L, Zheng C, Tang H, Li J, Zheng H, Yang B, et al. Immunotherapy in bone and soft-tissue tumors: Current advances and future directions. Orthopedics and Tissue Engineering. 2026;1(2):025360015. doi:10.36922/ote025360015

BibTeX
@article{Fang2026,
  author = {Fang, Li and Zheng, Chong and Tang, Haijun and Li, Jian and Zheng, Haohong and Yang, Bin and Li, Xiaodan and Wang, Jian and Li, Jianlong},
  title = {Immunotherapy in bone and soft-tissue tumors: Current advances and future directions},
  journal = {Orthopedics and Tissue Engineering},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {025360015},
  doi = {10.36922/ote025360015}
}
Kostenlos starten →